Table 1.
Baseline characteristics
| Variable | Total N = 54 (100%) |
Concentration EFV < 4.0 ng/mL N = 48 (88.9%) |
Concentration EFV ≥ 4.0 ng/mL N = 6 (11.1%) |
p value |
|---|---|---|---|---|
| Age, in years | 41 (11) | 41 (11) | 43 (11) | 0.81 |
| High educational attainment according to Verhage (group 6 and 7), N (%) | 26 (48.1) | 23 (47.9) | 3 (50.0) | 0.63 |
|
Employed N (%) |
51 (94.4) | 47 (97.9) | 4 (66.7) | 0.03 |
| BMI, in kg/m2 mean ± SD | 24.1 ± 3.3 | 24.1 ± 3.5 | 23.4 ± 2.7 | 0.52 |
| Use of neuropsychiatric medication, N (%) | 7 (13.0) | 6 (12.5) | 1 (16.7) | 0.58 |
| cART, in months | 58 (51) | 58 (50) | 58 (85) | 0.99 |
| EFV treatment duration, in months mean ± SD | 56 ± 28 | 56 ± 29 | 56 ± 24 | 0.88 |
| CD4 count, in cell/mm3 | 605 (268) | 620 (255) | 546 (365) | 0.46 |
| CD4 nadir, in cell/mm3 | 295 (138) | 275 (144) | 355 (100) | 0.05 |
| HIV disease duration, in months | 92 (56) | 92 (51) | 85 (140) | 0.85 |
| EFV concentration, in mg/L | 2.16 (1.50) | 1.80 (1.31) | 7.11 (9.67) | <0.01 |
| Plasma NFL, in pg/mL | 21.6 (16.6) | 21.6 (16.8) | 20.7 (24.3) | 0.82 |
Values shown as median (IQR), unless otherwise specified
*Difference considered significant (p value < 0.05)
N number, EFV efavirenz, IQR interquartile range, BMI body mass index, SD standard deviation, cART combination antiretroviral therapy, HIV human immunodeficiency virus, NFL neurofilament light